Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 307Lung Neoplasms 111Pancreatic Neoplasms 70Neoplasms 56Neoplasm Metastasis 32Brain Neoplasms 31Head and Neck Neoplasms 26Squamous Cell Carcinoma of Head and Neck 25Breast Neoplasms 25Glioblastoma 24Adenocarcinoma of Lung 23Gliosarcoma 22Non-Squamous Non-Small Cell Lung Cancer 21Colorectal Neoplasms 18Carcinoma, Hepatocellular 17Adenocarcinoma, Bronchiolo-Alveolar 16Rectal Neoplasms 13Colonic Neoplasms 13Carcinoma, Renal Cell 13Glioma 12Esophageal Neoplasms 11Astrocytoma 11Central Nervous System Neoplasms 9Carcinoma, Squamous Cell 9Salivary Gland Neoplasms 8Prostatic Neoplasms 8Oligodendroglioma 8Gallbladder Neoplasms 8Adenocarcinoma 8Ovarian Neoplasms 7

Interventions

camrelizumab 2Radiation 2sintilimab 1Tumor Burden 1Pyloromyotomy 1Paclitaxel 1Ocoxin 1Itraconazole 1Fluorouracil 1Esophagectomy 1Erlotinib Hydrochloride 1Cisplatin 1Botulinum Toxins, Type A 1Blood Specimen Collection 1Biopsy 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Esophageal Diseases × Erlotinib Hydrochloride × Clear all
NCT00442507 2015-07-24

OSI3650

Washington University School of Medicine

Phase 2 Terminated
6 enrolled 7 charts
Gastrointestinal

Esophageal Diseases, Esophageal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡